Industry News
Imugene licenses poultry productivity product to Merial
Sydney animal-health biotech Imugene (ASX:IMU) has finalised an exclusive sub-license agreement granting international livestock health company and Merck-Aventis subsidiary Merial the global rights to develop and sell Imugene's poultry productivity enhancing product. [ + ]
Panbio develops new type of antibody assay
Brisbane medical diagnostics developed Panbio (ASX:PBO) believes it has achieved a milestone in its efforts to develop a new type of antibody assay capable of directly detecting target antigens at low concentrations in antigenically complex biological fluids. [ + ]
In brief: Living Cell Technologies, Phosphagenics, Rockeby, Antisense, Prima, Proteome Systems
Living Cell Technologies (ASX:LCT) has appointed US based neuroscientist Dr Dwaine F Emerich as chief scientific officer of LCT BioPharma. He has been LCT's US vice-president of research since 2003, joining the company from Sertoli Technologies. [ + ]
Mini analysis tools coming to market
Scientists at the University of York, who have developed miniaturised tools for chemical and biological analysis, have won a major injection of growth capital to produce them commercially.
[ + ]Norwood to commence phase II cancer vaccine trial
Melbourne immune therapy developer Norwood Immunology (AIM:NIM) has signed an agreement for a phase II collaboration with the University of Texas MD Anderson Cancer Centre of Houston to determine whether its investigational melanoma cancer vaccine generates an enhanced immune response. [ + ]
Resonance Health patent granted
Perth based Resonance Health (ASX:RHT) has been granted its first European patent. [ + ]
Prozac prevents onset of Huntington's disease in mice
A collaborative study by Australian and UK neuroscientists has shown that the anti-depressant fluoxetine (Prozac) prevents the onset of Huntington's disease (HD) in transgenic HD mice. [ + ]
Funding for medical research and Thank You Day campaign launch
The latest commonwealth government funding announcement for health and medical research will see AUD$292 million allocated to more than 600 projects across 52 Australian universities, hospitals and medical research institutes. [ + ]
Peplin obtains positive anti-leukemia results for drug candidate in mouse model
Peplin (ASX:PEP) has produced positive results from an initial efficacy study of its drug candidate PEP005 IV in a mouse model of acute myeloid leukemia. [ + ]
Single cell research
Using a water droplet 1 trillion times smaller than a litre of soda as a sort of nanoscale test tube, a University of Washington scientist is conducting chemical analysis and experimentation at unprecedented tiny scales.
[ + ]Avantogen signs license agreement with Hawaii Biotech
Avantogen (ASX:ACU), formerly Australian Cancer Technology, has signed a worldwide, nonexclusive license agreement with Hawaii Biotech to evaluate Avantogen's proprietary adjuvant GPI-0100 with a series of vaccines. [ + ]
Anadis to sell Travelan in USA
Melbourne biopharmaceutical company Anadis (ASX:ANX) has received legal advice that its over-the-counter traveller's diarrhoea product, Travelan, complies with all US federal and state regulations for sale in the dietary and medical foods categories. [ + ]
Researchers address the meaning of the genomic revolution
Genetics genomics have disturbed science's dreams of explaining human nature and individuality as merely a function of the activity of genes, modulated by environmental factors, according to University of Queensland Federation Fellow Professor Paul Griffiths. [ + ]
AtCor Medical to list on ASX in November
Sydney-based devices company AtCor Medical has lodged its prospectus for an initial public offering (IPO) to raise AUD$15 million for expanding the US marketing and sales of its cardiovascular diagnostic device, SphygmoCor. [ + ]
A wee step forward
Physicists in Singapore have created the first paper battery that generates electricity from urine.
[ + ]
